CD276 and osteosarcoma: However, newer checkpoint molecules such as LAG-3, TIM-3, T cell immunoreceptor with Ig and ITIM domains (TIGIT), V-domain Ig suppressor of T cell activation (VISTA), and B7-H3 (CD276) have gained increasing attention as potential targets in osteosarcoma.